INCA033989
Based on 1 Customer Validation
INCA033989 is a fully human IgG1 monoclonal antibody targeting mutCALR (KD = 1.75 nM for mutCALRdel52; KD = 6.78 nM for mutCALRins5). INCA033989 antagonizes mutCALR-driven signaling and proliferation. INCA033989 selectively inhibits pSTAT3/pSTAT5. INCA033989 prevents thrombocytosis and reduces the expansion of mutCALR-positive cells. INCA033989 is useful for research on myeloproliferative neoplasms .
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.12%
- Peso molecular:143.9 kDa
-
Almacenamiento:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
Isotype
Human IgG1 lambda2
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
|
STAT3 |
STAT5 |
In Vitro
INCA033989 binds to recombinant mutCALRdel52 and mutCALRins5 proteins with nanomolar affinities (KD = 1.75 nM for mutCALRdel52; 6.78 nM for mutCALRins5), showing slight preferential binding to mutCALRdel52[1].
INCA033989 (72 h) selectively inhibits cytokine-independent proliferation of Ba/F3-TPOR/CALRdel52 and UT-7-TPOR/CALRdel52 cells (IC50 = 0.1 μg/mL; IC90 = 1 μg/mL)[1].
INCA033989 (4 h) broadly inhibits mutCALR-driven oncogenic signaling (including pSTAT5) in Ba/F3-TPOR/CALRdel52 cells[1].
INCA033989 (4 h) does not induce complement-dependent cytotoxicity in TF-1-TPOR/CALRdel52 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
INCA033989 (3-10 mg/kg; i.p.; twice weekly; 10 weeks) prevents thrombocytosis, reduces mutCALR-positive cell expansion, and normalizes bone marrow histology in C57BL/6 (CD45.2+; lethally irradiated recipients), CD45.2+ floxed homozygous CALRdel52 KI, CD45.2+ wt transgenic (UBI-GFP/BL6) mice model of Myeloproliferative neoplasm [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD scid gamma (NSG)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; single dose
-
Result:Decreased numbers of Ba/F3 cells in the blood, reduced spleen weight compared to isotype control, and achieved a plasma concentration of 50 μg/mL on day 13
-
Animal Model:C57BL/6 (CD45.2+; lethally irradiated recipients); CD45.2+ floxed homozygous CALRdel52 KI; CD45.2+ wt transgenic (UBI-GFP/BL6)[1]
-
Dosage:3-10 mg/kg
-
Administration:i.p.; twice weekly; 10 weeks
-
Result:Prevented thrombocytosis with platelet counts remaining within normal range, inhibited expansion of mutCALR-positive platelets (36% vs 96% in isotype control), reduced mutCALR-positive long-term hematopoietic stem cells (32% vs 85% in isotype control), and normalized bone marrow histology with normal megakaryocyte numbers
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
P27797
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Aplicación
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Peso molecular 143.9 kDa
-
Color Colorless to light yellow
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- INCA033989
- INCA 033989
- INCA-033989
- STAT
- UT-7-TPOR/CALRdel52
- mutated calreticulin
- disease-initiating cells
- mutCALR
- MPN
- dynamin-mediated endocytosis
- floxed homozygous CALRdel52 KI
- megakaryocyte
- TF-1-TPOR/CALRdel52
- JAK2V617F-positive cells
- mutCALRdel52
- hematopoiesis
- Ba/F3-TPOR/CALRdel52
- bone marrow
- UBI-GFP/BL6
- lysosomal degradation
- mutCALRins5
- Ba/F3-EPOR/JAK2V617F
- pSTAT5
- NOD scid gamma (NSG) mice
- myeloproliferative neoplasms
- primary CD34+ cells
- C57BL/6
- primary CD34? HSPCs
- TPOR
- thrombocytosis
- CD45.2+
- Inhibitor
- inhibitor
- inhibit